Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today announced that in a Phase 3 study, motavizumab was shown to reduce hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in motavizumab; p<0.001), as the trial's primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

Motavizumab is an investigational monoclonal antibody (MAb) being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This Phase 3 trial involved 1,410 full-term infants less than six months of age in two Native American populations. In previous medical studies these populations were shown to have high rates of hospitalization due to RSV.

The randomized (2:1), double-blind study was designed to compare monthly intramuscular injections of motavizumab against placebo. After an interim analysis conducted by an independent data safety monitoring committee, the study was unblinded early due to statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs requiring outpatient medical management within this population. Kate O'Brien, M.D., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, served as the study's principal investigator.

"We are pleased with the results of this study which support the positive results seen in our Phase 3 pivotal trial comparing motavizumab and Synagis(R) (palivizumab) that were previously reported at the Pediatric Academic Societies meeting in May 2007," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease, MedImmune.

Motavizumab was well tolerated in these
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ctober 7 /-,Sosei Group Cor...ctura,Group plc ("Vectura"; LSE: VEC), announce re...acy, safety and tolerability of NVA237 presented a...Society (ERS) in Berlin,Germany. The new data sho...haled long-acting muscarinic antagonist (LAMA), pr...
(Date:10/6/2008)...to the understanding of and possible trea...BILLERICA, Mass., Oct. 6 /- Seahorse ...t ever analytical instrument for the,kinetic measu...oplasmic,glycolysis in cells in a 96 well micropla...ular bioenergetics have been relatively unchanged ...
(Date:10/6/2008)... at The American College of Nutrition ...6 /- New research on the benefits of,...t The American College of,Nutrition (ACN) Annual M...Probiotics in Health and Disease." Scientific expe...ion discussed the potential uses for,probiotics in...
(Date:10/6/2008)...E, Oct. 6 /- Complete,Genomics Inc., ...quencing,company, and the Institute for Systems Bi...onduct populationwide human genome studies., In p...e its proprietary,DNA sequencing technology to seq...hen, once proof-of-concept has been demonstrated, ...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 2'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 4Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 8958 1New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 8958 2New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 8958 3Journal Sleep 3A A short term dose of zolpidem is an effective treatment for insomnia 8956 1Journal Sleep 3A A short term dose of zolpidem is an effective treatment for insomnia 8956 2Research suggests new treatment suitable for all patients 8954 1Research suggests new treatment suitable for all patients 8954 2Research suggests new treatment suitable for all patients 8954 3Silence may lead to phantom noises misinterpreted as tinnitus 8952 1
(Date:10/7/2008)... Moores Cancer Center at the University of Califor...ave off the relentless march of advanced lung canc...r vaccine. While many vaccines attempt to pump up ...accine, Lucanix, is genetically engineered to also...em-suppressing activities. , The first patients ...
(Date:10/7/2008)...ment of planned bequest comes at stem cell symposi...re/ -- Just over one year,ago, retail pioneer A. A...University of Michigan, to endow a new research in...nting human disease., Today, at the institute,s f... he will bequeath an additional $22 million to the...
(Date:10/7/2008)...0 PEOPLE ACROSS THE NATION HAVE SAID ,I VOTE FOR T...S, Oct. 7 /PRNewswire/ -- To aid and help educate ... positions of presidential candidates,Senators Joh...ancer issues,the Susan G. Komen for the Cure(R) A...ces available on its web site --, http://www.IVote...
(Date:10/7/2008)... Wyndstorm Corporation ( www.wyndstorm.com ) ...ompany, announced a key win with Muve, Inc. ( www....plan program design to promote Muve,s activity-bas...project will ultimately help Muve,s corporate clie...oyees via interactive messaging, rewards programs,...
Breaking Medicine News(10 mins):Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 3Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3
...claim to the highest autism rate in America, have ...to autism and provide lifetime care for those wit...utism, the largest so far, has found that about 1 ...est rate 1 in 94 children found in New Jersey. ...
...tronic nose device which may be used to diagnose t...s at Leiden University Medical Center in the Nethe... a newer version of a sensor that has been used in...es, contains chemical vapour sensors that react to...
...male impotence drug Viagra may be useful for treat...r the treatment of high blood pressure and angina,...levels of a naturally-occurring compound, cyclic g...GMP). In the brain, cGMP has a vital function in ...
...that topical application of a gel made from platel...ds heal more quickly and completely . Recent inno... into a concentrated plasma rich in platelets (par...), and then to an autologous (from the patients ow...
Other Medicine News:Health News:American State Lawmakers Make Moves To Tackle Autism 2Health News:Electronic Nose to Diagnose the Severity of Asthma 2Health News:Gel Made of Patients Own Platelets may Speed Up Wound Healing 2
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: